Format

Send to

Choose Destination
Biochemistry (Mosc). 2016 Nov;81(11):1396-1400.

Immunogenicity of Human Interferon-Beta-Containing Pharmaceuticals.

Author information

1
Center for Molecular Medicine, Pavlov First Saint Petersburg State Medical University, St. Petersburg, 197022, Russia. Nazarov19932@mail.ru.

Abstract

Multiple sclerosis is a severe autoimmune disease with inflammatory component that continues to be resistant to treatment. One of the approaches retarding its progression is based on using nonspecific therapy with human interferon-beta (IFN-β)-containing pharmaceuticals. Neutralizing antibodies (NAbs) against genetically engineered pharmaceuticals developed by the patient's immune system, which reduce their therapeutic and biological activity, pose a serious problem. Cell lines sensitive to IFN-β activity also quantifying NAb level are applied because direct measurement of IFN-β antiviral activity is complicated. This study was aimed at standardization and validation of a reporter cell system for measuring anti-human IFN-β NAb titers, and evaluation data were obtained with samples from 33 patients with multiple sclerosis.

PMID:
27914464
DOI:
10.1134/S000629791611016X
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Biochemistry (Moscow)
Loading ...
Support Center